BRGX
BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. It also develops TruScan.Ai mobile app/website that integrates additional health indicators; and VitalWellness app, which merge its DNA and epigenetics platform. In addition, the company operates a social media content management platform, including its interactive search engine. Further, it provides DocSun Artificial Intelligence (AI) Engine, which integrates advanced ballistocardiography that detects an individual's heartbeat without touch; photoplethysmography, a method that uses light to track the flow of blood; and distributes wellness devices. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.00 | $426,175 | $26,630 |
| 2025 Q4 | -0.00 | $385,641 | $66,579 |
| 2025 Q3 | -0.00 | $507,755 | -$77,564 |
| 2025 Q2 | -0.00 | $445,970 | $3,205 |
| 2025 Q1 | -0.00 | $515,147 | $37,695 |
| 2024 Q4 | -0.02 | $460,489 | $18M |
| 2024 Q3 | -0.00 | $596,037 | $18M |
| 2024 Q2 | -0.00 | $734,032 | $19M |